Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.

导出 OA

翻译打印收藏纠错

作者： David E,Lanfear ^[1] ; Jasmine A,Luzum ^[2] ; Ruicong,She ^[1] ; Hongsheng,Gui ^[3] ; Mark P,Donahue ^[1] ; Christopher M,O'Connor ^[4] ; Kirkwood F,Adams ^[1] ; Sandra,Sanders-van Wijk ^[5] ; Nicole,Zeld ^[6] ; Micha T,Maeder ^[7] ; Hani N,Sabbah ^[8] ; William E,Kraus ^[1] ; Hans-Peter,Brunner-LaRocca ^[9] ; Jia,Li ^[2] ; L Keoki,Williams ^[5]

作者单位： Department of Internal Medicine, Center for Individualized and Genomic Medicine Research (D.E.L., J.A.L., R.S., H.G., N.Z., J.L., L.K.W.), Henry Ford Hospital, Detroit, MI. ^[1] Heart and Vascular Institute (D.E.L., H.N.S., J.L.), Henry Ford Hospital, Detroit, MI. ^[2] Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor (J.A.L.). ^[3] Department of Public Health Sciences (R.S.), Henry Ford Hospital, Detroit, MI. ^[4] Division of Cardiology, Duke University, Durham, NC (M.P.D., W.E.K.). ^[5] Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.). ^[6] Division of Cardiology, University of North Carolina, Chapel Hill (K.F.A.). ^[7] Department of Cardiology, Maastricht University, the Netherlands (S.S.-v.W., H.-P.B.-L.). ^[8] Cardiology Department, Kantonsspital St. Gallen, Switzerland (M.T.M.). ^[9]

关键词 atrial fibrillation pharmacogenetics population groups precision medicine